Primary overall survival analysis from the Phase 3 monarchE study of Verzenio (abemaciclib) in HR+HER2-, node-positive, high-risk early breast cancer to ...

Radiographic Progression-Free Survival and Clinical Progression-Free Survival as Potential Surrogates for Overall Survival in Men With Metastatic Hormone-Sensitive Prostate Cancer Patients with ...

Which of the statements about the American College of Rheumatology guidance statement for diagnosing and managing VEXAS are correct?

BN001, a signal seeking Phase II randomized trial, indicated that photon radiation dose intensification (75 Gy) did not ...

We recently compiled a list of the 12 Healthcare Stocks with Insider Buying in 2025. ImmunityBio, Inc. is one of them.

ImmunityBio, Inc. (NASDAQ:IBRX) is one of the Best Penny Stocks to Buy with the Highest Upside Potential. On September 8, ImmunityBio, Inc. (NASDAQ:IBRX) announced new findings from its Phase 2 ...

A new review highlights sepsis-induced immunosuppression as a key driver of mortality, summarizing current research and ...

In 2025, there will be a complicated combination of opportunities and difficulties in the healthcare innovation landscape, ...

iCenter for Paediatric Endocrinology, Diabetology, and Clinical Research, Auf Der Bult Children's Hospital, Hannover, Germany jDepartment of Endocrinology, Diabetes, and Metabolic Diseases, University ...

Primary antibody deficiencies (PADs) are a heterogeneous spectrum of conditions characterized by the marked reduction in blood levels of at least one main immunoglobulin (Ig) class. PADs account for ...

In the phase 2 EXTEND trial, investigators randomly assigned patients with oligometastatic prostate cancer to ADT or MDT + ADT, with further stratification by intermittent vs continuous ADT that was ...